Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV

被引:14
|
作者
Milic, Jovana [1 ,2 ]
Menozzi, Valentina [3 ]
Schepis, Filippo [4 ]
Malagoli, Andrea [1 ]
Besutti, Giulia [2 ]
Franconi, Iacopo [1 ]
Raimondi, Alessandro [1 ]
Carli, Federica [1 ]
Mussini, Cristina [1 ]
Sebastiani, Giada [5 ]
Guaraldi, Giovanni [1 ]
机构
[1] Univ Modena & Reggio Emilia, Modena HIV Metab Clin, Modena, Italy
[2] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy
[3] Univ Modena & Reggio Emilia, Modena, Italy
[4] Univ Modena & Reggio Emilia, Dept Gastroenterol, Modena, Italy
[5] McGill Univ, Dept Med, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ, Canada
关键词
frailty; HIV; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; METABOLIC SYNDROME; STEATOHEPATITIS; MANAGEMENT; DIAGNOSIS; OBESITY; NAFLD;
D O I
10.1097/QAD.0000000000002650
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The aim was to investigate the contribution of liver steatosis and significant fibrosis alone and in association [nonalcoholic fatty liver disease (NAFLD) with fibrosis] to frailty as a measure of biological age in people living with HIV (PLWH). Design: This was a cross-sectional study of consecutive patients attending Modena HIV Metabolic Clinic in 2018-2019. Methods: Patients with hazardous alcohol intake and viral hepatitis coinfection were excluded. Liver steatosis was diagnosed by controlled attenuation parameter (CAP), while liver fibrosis was diagnosed by liver stiffness measurement (LSM). NAFLD was defined as presence of liver steatosis (CAP >= 248 dB/m), while significant liver fibrosis or cirrhosis (stage >= F2) as LSM at least 7.1 kPa. Frailty was assessed using a 36-Item frailty index. Logistic regression was used to explore predictors of frailty using steatosis and fibrosis as covariates. Results: We analysed 707 PLWH (mean age 53.5 years, 76.2% men, median CD4(+) cell count 700 cells/mu l, 98.7% with undetectable HIV RNA). NAFLD with fibrosis was present in 10.2%; 18.9 and 3.9% of patients were classified as frail and most-frail, respectively. Univariate analysis demonstrated that neurocognitive impairment [odds ratio (OR) = 5.1, 1.6-15], vitamin D insufficiency (OR = 1.94, 1.2-3.2), obesity (OR = 8.1, 4.4-14.6), diabetes (OR = 3.2, 1.9-5.6), metabolic syndrome (OR = 2.41, 1.47-3.95) and osteoporosis (OR = 0.37, 0.16-0.76) were significantly associated with NAFLD with fibrosis. Predictors of frailty index included steatosis (OR = 2.1, 1.3-3.5), fibrosis (OR = 2, 1-3.7), NAFLD with fibrosis (OR = 9.2, 5.2-16.8), diabetes (OR = 1.7, 1-2.7) and multimorbidity (OR = 2.5, 1.5-4). Conclusion: Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH. Copyright (C) 2020 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1915 / 1921
页数:7
相关论文
共 50 条
  • [41] Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese
    Ooi, Geraldine J.
    Burton, Paul R.
    Doyle, Lisa
    Wentworth, John M.
    Bhathal, Prithi S.
    Sikaris, Ken
    Cowley, Michael A.
    Roberts, Stuart K.
    Kemp, William
    O'Brien, Paul E.
    Brown, Wendy A.
    OBESITY SURGERY, 2017, 27 (01) : 115 - 125
  • [42] Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    Kim, Yejin
    Chang, Yoosoo
    Cho, Yong Kyun
    Ahn, Jiin
    Shin, Hocheol
    Ryu, Seungho
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (03) : 543 - +
  • [43] Metabolic aspects of adult patients with nonalcoholic fatty liver disease
    Abenavoli, Ludovico
    Milic, Natasa
    Di Renzo, Laura
    Preveden, Tomislav
    Medic-Stojanoska, Milica
    De Lorenzo, Antonino
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (31) : 7006 - 7016
  • [44] Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease
    Giorgio, Valentina
    Mosca, Antonella
    Alterio, Arianna
    Alisi, Anna
    Grieco, Antonio
    Nobili, Valerio
    Miele, Luca
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 65 (02) : 150 - 155
  • [45] Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in HIV infection: a metabolic approach of an infectious disease
    Esteban Coronel-Castillo, Carlos
    Qi, Xingshun
    Contreras-Carmona, Jocelyn
    Lenin Ramirez-Perez, Oscar
    Mendez-Sanchez, Nahum
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (06) : 531 - 540
  • [46] A clinical model to predict fibrosis on liver biopsy in paediatric subjects with nonalcoholic fatty liver disease
    Kulkarni, Sakil
    Naz, Nadia
    Gu, Hongjie
    Stoll, Janis M.
    Thompson, Michael D.
    DeBosch, Brian J.
    CLINICAL OBESITY, 2021, 11 (05)
  • [47] The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    Dai, Chia-Yen
    Fang, Tzu-Jung
    Hung, Wei-Wen
    Tsai, Hui-Ju
    Tsai, Yi-Chun
    BIOMEDICINES, 2022, 10 (07)
  • [48] Association of nonalcoholic fatty liver disease and liver cancer
    Schulz, Perla Oliveira
    Ferreira, Fabio Goncalves
    Araujo Nascimento, Maria de Fatima
    Vieira, Andrea
    Ribeiro, Mauricio Alves
    David, Andre Ibrahim
    Szutan, Luiz Arnaldo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (03) : 913 - 918
  • [49] Role of liver biopsy in nonalcoholic fatty liver disease
    Nalbantoglu, ILKe
    Brunt, Elizabeth M.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (27) : 9026 - 9037
  • [50] Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease
    Lee, Hye Won
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Kim, Kwang Joon
    Han, Kwang-Hyub
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (08) : 2150 - 2158